Bristol Myers Squibb Sees Unusually Large Options Volume (NYSE:BMY)

Bristol Myers Squibb Company (NYSE:BMY) was the recipient of unusually large options trading on Thursday. Traders acquired 44,620 put options on the stock. This is an increase of 77% compared to the typical volume of 25,257 put options.

Bristol Myers Squibb Stock Performance

Shares of BMY opened at $64.98 on Friday. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. The stock has a 50-day moving average of $57.90 and a 200-day moving average of $58.29. The company has a market cap of $132.70 billion, a PE ratio of 18.25, a P/E/G ratio of 0.18 and a beta of 0.23. Bristol Myers Squibb has a one year low of $42.52 and a one year high of $65.56.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The business had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm’s revenue was up 5.7% compared to the same quarter last year. During the same period in the previous year, the company posted $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, equities research analysts predict that Bristol Myers Squibb will post 6.34 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be given a $0.63 dividend. The ex-dividend date of this dividend is Thursday, July 2nd. This represents a $2.52 annualized dividend and a yield of 3.9%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 70.79%.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers reported second-quarter adjusted EPS of $2.04, well above the $1.60 analyst consensus and up from $1.46 a year earlier. Revenue increased 5.7% year over year to $12.97 billion, exceeding estimates of approximately $11.74 billion. Bristol Myers raises 2026 forecast as Eliquis and newer medicines power results
• Positive Sentiment: The company raised its full-year 2026 outlook to EPS of $6.75-$7.00 and revenue of $49 billion-$50 billion, above consensus forecasts. Management cited strong performance from blood thinner Eliquis and newer products including Camzyos and Reblozyl. Bristol Myers Squibb raises 2026 revenue outlook
• Positive Sentiment: The growth portfolio reportedly expanded 14%, with continued momentum from Opdivo Qvantig, Breyanzi and Iza-bren. Strong cash flow and a valuation viewed as inexpensive relative to large pharmaceutical peers, along with a dividend yield near 4%, supported bullish analyst commentary. Bristol Myers Squibb upgraded to Buy on positive earnings and outlook
• Neutral Sentiment: Analysts noted that the transition away from older products remains incomplete. Opdivo sales declined, while patent expirations and legacy portfolio weakness continue to pressure revenue.
• Negative Sentiment: Delayed clinical readouts for Milvexian and Cobenfy, as well as mixed performance from certain pipeline assets, may limit near-term catalysts. Unusually heavy put-option activity also signals that some traders remain cautious about downside risks. Bristol Myers Squibb second-quarter earnings call highlights

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Swiss RE Ltd. bought a new stake in shares of Bristol Myers Squibb during the fourth quarter worth about $25,000. Physician Wealth Advisors Inc. lifted its position in Bristol Myers Squibb by 73.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 202 shares in the last quarter. Darwin Wealth Management LLC bought a new position in Bristol Myers Squibb in the 2nd quarter valued at about $25,000. Bayban acquired a new position in Bristol Myers Squibb during the 4th quarter valued at about $31,000. Finally, EQ Wealth Advisors LLC bought a new stake in Bristol Myers Squibb during the 4th quarter worth approximately $32,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on BMY. UBS Group restated a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $54.00 target price on shares of Bristol Myers Squibb in a report on Monday, July 6th. Bank of America dropped their price target on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating on the stock in a research note on Friday, July 10th. Weiss Ratings cut Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, July 16th. Finally, Raymond James Financial reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday. Eight research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $61.25.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.